Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 95

1.

Safety and effectiveness of direct oral anticoagulants following ultrasound-assisted catheter directed thrombolysis for venous thromboembolism.

Kelley D, Wright L, Ohman K, Ferreira J.

J Thromb Thrombolysis. 2018 Jul;46(1):58-61. doi: 10.1007/s11239-018-1682-6.

PMID:
29797208
2.

Modified forest rotation lengths: Long-term effects on landscape-scale habitat availability for specialized species.

Roberge JM, Öhman K, Lämås T, Felton A, Ranius T, Lundmark T, Nordin A.

J Environ Manage. 2018 Mar 15;210:1-9. doi: 10.1016/j.jenvman.2017.12.022. Epub 2018 Jan 9.

PMID:
29329003
3.

Surgeon Variation in Intraoperative Supply Cost for Pancreaticoduodenectomy: Is Intraoperative Supply Cost Associated with Outcomes?

Brauer DG, Ohman KA, Jaques DP, Woolsey CA, Wu N, Liu J, Doyle MBM, Fields RC, Chapman WC, Strasberg SM, Hawkins WG.

J Am Coll Surg. 2018 Jan;226(1):37-45.e1. doi: 10.1016/j.jamcollsurg.2017.10.007. Epub 2017 Oct 19.

4.

Combination of Oral Antibiotics and Mechanical Bowel Preparation Reduces Surgical Site Infection in Colorectal Surgery.

Ohman KA, Wan L, Guthrie T, Johnston B, Leinicke JA, Glasgow SC, Hunt SR, Mutch MG, Wise PE, Silviera ML.

J Am Coll Surg. 2017 Oct;225(4):465-471. doi: 10.1016/j.jamcollsurg.2017.06.011. Epub 2017 Jul 6.

PMID:
28690206
5.

Projecting biodiversity and wood production in future forest landscapes: 15 key modeling considerations.

Felton A, Ranius T, Roberge JM, Öhman K, Lämås T, Hynynen J, Juutinen A, Mönkkönen M, Nilsson U, Lundmark T, Nordin A.

J Environ Manage. 2017 Jul 15;197:404-414. doi: 10.1016/j.jenvman.2017.04.001. Epub 2017 Apr 12.

PMID:
28411568
6.

Interferon-based chemoradiation followed by gemcitabine for resected pancreatic adenocarcinoma: long-term follow-up.

Ohman KA, Liu J, Linehan DC, Tan MC, Tan BR, Fields RC, Strasberg SM, Hawkins WG.

HPB (Oxford). 2017 May;19(5):449-457. doi: 10.1016/j.hpb.2017.01.012. Epub 2017 Feb 3.

7.

Conjugation to the sigma-2 ligand SV119 overcomes uptake blockade and converts dm-Erastin into a potent pancreatic cancer therapeutic.

Ohman KA, Hashim YM, Vangveravong S, Nywening TM, Cullinan DR, Goedegebuure SP, Liu J, Van Tine BA, Tiriac H, Tuveson DA, DeNardo DG, Spitzer D, Mach RH, Hawkins WG.

Oncotarget. 2016 Jun 7;7(23):33529-41. doi: 10.18632/oncotarget.9551.

8.

Considering Future Potential Regarding Structural Diversity in Selection of Forest Reserves.

Lundström J, Öhman K, Rönnqvist M, Gustafsson L.

PLoS One. 2016 Feb 11;11(2):e0148960. doi: 10.1371/journal.pone.0148960. eCollection 2016.

9.

Symptomatic carotid near-occlusion with full collapse might cause a very high risk of stroke.

Johansson E, Öhman K, Wester P.

J Intern Med. 2015 May;277(5):615-23. doi: 10.1111/joim.12318. Epub 2014 Nov 13.

10.

Pharmacokinetic-pharmacodynamic assessment of the interrelationships between tesaglitazar exposure and renal function in patients with type 2 diabetes mellitus.

Hamrén B, Ohman KP, Svensson MK, Karlsson MO.

J Clin Pharmacol. 2012 Sep;52(9):1317-27. doi: 10.1177/0091270011416937. Epub 2011 Nov 1.

PMID:
22045829
11.

Cost-effective age structure and geographical distribution of boreal forest reserves.

Lundström J, Ohman K, Perhans K, Rönnqvist M, Gustafsson L, Bugman H.

J Appl Ecol. 2011 Feb;48(1):133-142.

12.

[Vitamin D deficiency in kidney failure. Risk factor for cardiovascular disease].

Ohman K, Larsson T, Spaak J.

Lakartidningen. 2010 Nov 17-23;107(46):2884-7. Review. Swedish. No abstract available.

PMID:
21197784
13.

Radicals in 5-methylcytosine induced by ionizing radiation. Electron magnetic resonance for structural and mechanistic analyses.

Krivokapić A, Ohman KT, Munthe M, Nelson WH, Hole EO, Sagstuen E.

Radiat Res. 2010 May;173(5):689-702. doi: 10.1667/RR2026.1.

PMID:
20426669
14.
15.

Using research to determine support for a policy on family presence during resuscitation.

Basol R, Ohman K, Simones J, Skillings K.

Dimens Crit Care Nurs. 2009 Sep-Oct;28(5):237-47; quiz 248-9. doi: 10.1097/DCC.0b013e3181ac4bf4.

PMID:
19700973
16.

Primary oxidation products of 5-methylcytosine: methyl dynamics and environmental influences.

Krivokapić A, Øhman KT, Nelson WH, Hole EO, Sagstuen E.

J Phys Chem A. 2009 Sep 3;113(35):9633-40. doi: 10.1021/jp904747j.

PMID:
19663491
17.

[Computer angiography and ultrasound equally good in the examination of carotid artery. The Carotis Center should have access to both].

Malm J, Ohman K, Backman C, Arnerlöv C.

Lakartidningen. 2009 Mar 18-24;106(12):850-3. Swedish. No abstract available.

PMID:
19452785
18.

Percutaneous biopsy of cavernous sinus tumour via the foramen ovale.

Yi W, Ohman K, Brännström T, Bergenheim AT.

Acta Neurochir (Wien). 2009 Apr;151(4):401-7; discussion 407. doi: 10.1007/s00701-009-0245-1.

PMID:
19266151
19.

Ionization energies of the nucleotides.

Close DM, Øhman KT.

J Phys Chem A. 2008 Nov 6;112(44):11207-12. doi: 10.1021/jp805308p. Epub 2008 Oct 15.

PMID:
18855364
20.

Free radical conformations and conversions in X-irradiated single crystals of L-cysteic acid by electron magnetic resonance and density functional theory studies.

Øhman KT, Sagstuen E.

J Phys Chem A. 2008 May 8;112(18):4284-93. doi: 10.1021/jp711821c. Epub 2008 Apr 16.

PMID:
18412406
21.

Improvement of postprandial lipid handling and glucose tolerance in a non-diabetic population by the dual PPARalpha/gamma agonist, tesaglitazar.

Fagerberg B, Schuster H, Birketvedt GS, Tonstad S, Ohman KP, Gause-Nilsson I; SIR Study Group.

Diab Vasc Dis Res. 2007 Sep;4(3):174-80.

PMID:
17907107
22.
23.

Tesaglitazar, a dual peroxisome proliferator-activated receptor alpha/gamma agonist, improves apolipoprotein levels in non-diabetic subjects with insulin resistance.

Schuster H, Fagerberg B, Edwards S, Halmos T, Lopatynski J, Stender S, Birketvedt GS, Tonstad S, Gause-Nilsson I, Halldórsdóttir S, Ohman KP; SIR Investigators.

Atherosclerosis. 2008 Mar;197(1):355-62. Epub 2007 Jul 13.

PMID:
17631296
24.

Development of a landfill model to prioritize design and operating objectives.

Ohman KV, Hettiaratchi JP, Ruwanpura J, Balakrishnan J, Achari G.

Environ Monit Assess. 2007 Dec;135(1-3):85-97. Epub 2007 May 10.

PMID:
17492360
25.

Prospective, randomized trial of the effectiveness and retention of 30-min layperson training for cardiopulmonary resuscitation and automated external defibrillators: The American Airlines Study.

Roppolo LP, Pepe PE, Campbell L, Ohman K, Kulkarni H, Miller R, Idris A, Bean L, Bettes TN, Idris AH.

Resuscitation. 2007 Aug;74(2):276-85. Epub 2007 Apr 23.

PMID:
17452070
26.

Effect of tesaglitazar, a dual PPAR alpha/gamma agonist, on glucose and lipid abnormalities in patients with type 2 diabetes: a 12-week dose-ranging trial.

Goldstein BJ, Rosenstock J, Anzalone D, Tou C, Ohman KP.

Curr Med Res Opin. 2006 Dec;22(12):2575-90.

PMID:
17166340
27.

Food does not affect the pharmacokinetics of tesaglitazar, a novel dual peroxisome proliferator-activated receptor alpha/gamma agonist.

Samuelsson S, Johansson S, Halldórsdóttir S, Stenhoff H, Ohman KP.

J Clin Pharmacol. 2006 Sep;46(9):1017-22.

PMID:
16920896
28.

Single crystals of L-O-serine phosphate X-irradiated at low temperatures: EPR, ENDOR, EIE, and DFT studies.

Øhman KT, Sanderud A, Hole EO, Sagstuen E.

J Phys Chem A. 2006 Aug 10;110(31):9585-96.

PMID:
16884191
29.

Subscores of the FAB differentiate frontotemporal lobar degeneration from AD.

Lipton AM, Ohman KA, Womack KB, Hynan LS, Ninman ET, Lacritz LH.

Neurology. 2005 Sep 13;65(5):726-31.

PMID:
16157906
30.

Pharmacokinetics and metabolism of tesaglitazar, a novel dual-acting peroxisome proliferator-activated receptor alpha/gamma agonist, after a single oral and intravenous dose in humans.

Ericsson H, Hamrén B, Bergstrand S, Elebring M, Fryklund L, Heijer M, Ohman KP.

Drug Metab Dispos. 2004 Sep;32(9):923-9.

PMID:
15319332
31.

Beta1-adrenergic receptor gene polymorphisms and response to beta1-adrenergic receptor blockade in patients with essential hypertension.

Karlsson J, Lind L, Hallberg P, Michaëlsson K, Kurland L, Kahan T, Malmqvist K, Ohman KP, Nyström F, Melhus H.

Clin Cardiol. 2004 Jun;27(6):347-50.

33.

Gender-specific association between preproendothelin-1 genotype and reduction of systolic blood pressure during antihypertensive treatment--results from the Swedish Irbesartan Left Ventricular Hypertrophy Investigation versus Atenolol (SILVHIA).

Hallberg P, Karlsson J, Lind L, Michaëlsson K, Kurland L, Kahan T, Malmqvist K, Ohman KP, Nyström F, Liljedahl U, Syvänen AC, Melhus H.

Clin Cardiol. 2004 May;27(5):287-90.

34.

Transforming growth factor beta1 genotype and change in left ventricular mass during antihypertensive treatment--results from the Swedish Irbesartan Left Ventricular Hypertrophy Investigation versus Atenolol (SILVHIA).

Hallberg P, Lind L, Billberger K, Michaelsson K, Karlsson J, Kurland L, Kahan T, Malmqvist K, Ohman KP, Nyström F, Liljedahl U, Syvänen AC, Melhus H.

Clin Cardiol. 2004 Mar;27(3):169-73.

36.

Adipocyte-derived leucine aminopeptidase genotype and response to antihypertensive therapy.

Hallberg P, Lind L, Michaëlsson K, Kurland L, Kahan T, Malmqvist K, Ohman KP, Nyström F, Liljedahl U, Syvänen AC, Melhus H.

BMC Cardiovasc Disord. 2003 Sep 18;3:11. Epub 2003 Sep 18.

37.
38.

Relationships between left ventricular mass and the renin-angiotensin system, catecholamines, insulin and leptin.

Malmqvist K, Ohman KP, Lind L, Nyström F, Kahan T.

J Intern Med. 2002 Nov;252(5):430-9.

39.

The CYP2C9 genotype predicts the blood pressure response to irbesartan: results from the Swedish Irbesartan Left Ventricular Hypertrophy Investigation vs Atenolol (SILVHIA) trial.

Hallberg P, Karlsson J, Kurland L, Lind L, Kahan T, Malmqvist K, Ohman KP, Nyström F, Melhus H.

J Hypertens. 2002 Oct;20(10):2089-93.

PMID:
12359989
41.

Angiotensin converting enzyme gene polymorphism predicts blood pressure response to angiotensin II receptor type 1 antagonist treatment in hypertensive patients.

Kurland L, Melhus H, Karlsson J, Kahan T, Malmqvist K, Ohman KP, Nyström F, Hägg A, Lind L; Swedish Irbesartan Left Ventricular Hypertrophy Investigation versus Atenolol (SILVHIA) Trial.

J Hypertens. 2001 Oct;19(10):1783-7.

PMID:
11593098
42.

Regression of left ventricular hypertrophy in human hypertension with irbesartan.

Malmqvist K, Kahan T, Edner M, Held C, Hägg A, Lind L, Müller-Brunotte R, Nyström F, Ohman KP, Osbakken MD, Ostergern J.

J Hypertens. 2001 Jun;19(6):1167-76.

PMID:
11403367
43.

Less difference between office and ambulatory blood pressure in women than in men both before and during antihypertensive treatment.

Nyström FH, Ohman KP, Isaksson H, Schwan A, Ostergren J.

Blood Press. 2000;9(6):340-5.

PMID:
11212063
44.

The transformational leadership of critical care nurse-managers.

Ohman KA.

Dimens Crit Care Nurs. 2000 Jan-Feb;19(1):46-54.

PMID:
10876489
45.

Nurse manager leadership.

Ohman KA.

J Nurs Adm. 1999 Dec;29(12):16, 21. No abstract available.

PMID:
10608935
46.

Plasma levels of cyclic GMP and endothelin in postmenopausal women with unstable coronary artery disease.

Nielsen NE, Ahlner J, Malmstedt J, Ohman KP, Swahn E.

Scand J Clin Lab Invest. 1999 Aug;59(5):325-34.

PMID:
10533844
47.

Pitfalls in Doppler evaluation of diastolic function: insights from 3-dimensional magnetic resonance imaging.

Fyrenius A, Wigström L, Bolger AF, Ebbers T, Ohman KP, Karlsson M, Wranne B, Engvall J.

J Am Soc Echocardiogr. 1999 Oct;12(10):817-26.

PMID:
10511650
48.

Effect of amlodipine versus felodipine extended release on 24-hour ambulatory blood pressure in hypertension.

Ostergren J, Isaksson H, Brodin U, Schwan A, Ohman KP.

Am J Hypertens. 1998 Jun;11(6 Pt 1):690-6.

PMID:
9657628
49.
50.

A population-based study of the white-coat blood pressure effect: positive correlation with plasma cortisol.

Nyström F, Aardal E, Ohman KP.

Clin Exp Hypertens. 1998 Jan;20(1):95-104.

PMID:
9507791

Supplemental Content

Support Center